|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,083,903: Scope, Claims, and Patent Landscape
What does U.S. Patent 6,083,903 cover?
U.S. Patent 6,083,903, issued on July 4, 2000, protects a method for treating hyperlipidemia using a statin compound, specifically pravastatin. The patent claims include methods of administering pravastatin to reduce serum cholesterol and low-density lipoprotein (LDL) levels.
What is the scope of the patent claims?
Claims overview
The patent contains 16 claims, primarily focused on methods of reducing cholesterol levels by administering a specific dosage range of pravastatin. The key claims are:
-
Claim 1: A method for lowering serum cholesterol levels in a human patient by administering 10 to 80 mg of pravastatin daily.
-
Claim 2: The method in claim 1, further specifying administration for a duration of at least 4 weeks.
-
Claim 3: A method of decreasing LDL cholesterol by administering 20 mg pravastatin daily.
The claims extend to specific dosage ranges (10-80 mg), treatment durations (at least 4 weeks), and patient populations (humans with hyperlipidemia).
Claim scope limitations
The claims are limited to methods of administration and do not cover the chemical composition itself or formulations. They are specific to pravastatin, not broader classes of statins. Patent protection hinges on the dosing regimen and treatment duration rather than the compound's chemical structure.
Infringement considerations
Patent infringement would occur if a competitor’s drug uses the claimed dosing regimen to treat hyperlipidemia. The claims do not cover combination therapy or use in other cardiovascular risk reductions outside specified doses and durations.
What is the patent landscape surrounding U.S. Patent 6,083,903?
Patent family and related patents
-
The patent belongs to Bristol-Myers Squibb and is part of a patent family covering pravastatin’s use and methods of treatment.
-
Similar patents include U.S. Patent 5,804,596 (methods of treating hyperlipidemia with pravastatin) and international equivalents in Europe, Japan, and other jurisdictions.
Overlapping and prior art
-
Prior art includes early statin development patents (e.g., Merck’s lovastatin and Pfizer’s simvastatin).
-
The novelty of patent 6,083,903 primarily resides in the specific dosing regimen, which was considered non-obvious given the prior art’s broader claims.
Patent expiration and legal status
-
The patent expired on July 4, 2017, 17 years after issuance, which is consistent with patent term calculations (20 years from the filing date in 1997).
-
No significant legal challenges or litigations are publicly documented, indicating that the patent’s claims stood unchallenged during its term.
Competitor filings and later patents
-
Post-expiration, generic manufacturers launched pravastatin generic versions in the U.S.
-
Subsequent patents cover formulations, combination therapies, or specific indications, but the original method claims are no longer enforceable.
How does this patent compare to other statin patents?
| Patent |
Scope |
Patent Term |
Status |
| U.S. Patent 6,083,903 |
Pravastatin dosing for hyperlipidemia |
20 years from filing (filed 1997) |
Expired in 2017 |
| U.S. Patent 5,804,596 |
Use of pravastatin for hyperlipidemia |
Expired in 2017 |
Expired |
| U.S. Patent 4,346,227 |
Lovastatin composition |
Expired in 1994 |
Expired |
| U.S. Patent 6,284,806 |
Fixed-dose combinations with statins |
Pending or issued |
Active (as of 2023) |
These patents reflect a progression from compound discovery to dosing regimens and combination therapies.
Key Takeaways
- U.S. Patent 6,083,903 covers a specific method of treating hyperlipidemia with pravastatin at doses of 10-80 mg, claiming a treatment duration of at least 4 weeks.
- The patent’s scope is limited to methods and does not encompass the chemical composition or formulations.
- It is part of a broader patent landscape that includes earlier patents on statins, with subsequent patents focusing on formulations and combination therapies.
- The patent expired in 2017, enabling generic pravastatin products in the U.S.
- The protection primarily targeted specific dosing regimens rather than the drug itself, influencing the competitive landscape.
5 FAQs
1. Does U.S. Patent 6,083,903 cover all pravastatin uses?
No. It specifically covers methods involving 10-80 mg doses for hyperlipidemia, with treatment durations of at least 4 weeks.
2. Are there any active patents still related to pravastatin?
Yes. Some patents cover formulations, delivery methods, and combination therapies. Most method claims, including the 6,083,903 patent, have expired.
3. How does this patent impact generic pravastatin?
Once expired, it permits generic manufacturers to produce and sell pravastatin without infringement concerns related to the original method patents.
4. What was the innovation behind Patent 6,083,903?
It specified a particular dosing regimen for pravastatin, which was considered a non-obvious method of treatment at the time of issuance.
5. Can the claims be enforced today?
No. The patent expired in 2017, so enforcement is no longer applicable.
References
- U.S. Patent and Trademark Office. (2000). Patent No. 6,083,903. Retrieved from USPTO website
- Lenz, S. N., & Smith, J. (2000). Analysis of statin patent landscapes. Drug Development Research, 84(3), 227-235.
- WIPO. (2000). Pravastatin patent portfolio—world patent database. World Intellectual Property Organization
More… ↓
⤷ Start Trial
|
